Asia-Pacific Neuropathic Pain Market – Industry Trends and Forecast to 2028

  • Healthcare
  • Published Report
  • Jun 2021
  • Asia-Pacific
  • 350 Pages
  • No of Tables: 278
  • No of Figures: 68

Asia-Pacific Neuropathic Pain Market, By Type (Spinal Cord Stimulation (SCS) Devices, External Peripheral Nerve Stimulation, Transcutaneous Electrical Nerve Stimulation (Tens) Devices), Product Type (Rechargeable and Non-Rechargeable), Procedure (Invasive and Non-Invasive), Technology (Transcutaneous Electrical Nerve Stimulation, Transcranial Magnetic Stimulation and Respiratory Electrical Stimulation), Modality (Stationary and Portable), Mode of Purchase (Over-the-Counter Devices and Prescription-Based Devices), Pain Type (Peripheral Neuropathy, Entrapment Neuropathy, Phantom Limb Neuropathy, Trigeminal Neuralgia, Post Herpetic Neuralgia (PHN), Post Traumatic Neuropathy, Foot Pain, Coccydynia), Indication (Spinal Stenosis, Chemotherapy-Induced Peripheral Neuropathy, Diabetic Neuropathy, Others), End User (Hospitals, Clinics, Home Healthcare, Ambulatory Surgical Centers and Others), Distribution Channel (Direct Tender, Third Party Distributor and Others), Country (China, South Korea, Japan, India, Australia, Singapore, Malaysia, Indonesia, Thailand, Philippines, Rest of Asia-Pacific) Industry Trends and Forecast to 2028

Asia-Pacific Neuropathic Pain Market Market Analysis and Insights: Asia-Pacific Neuropathic Pain Market

The neuropathic pain market is expected to gain market growth in the forecast period of 2021 to 2028. Data Bridge Market Research analyses that the market is growing with a CAGR of 9.2% in the forecast period of 2021 to 2028 and is expected to reach USD 9,124.84 million by 2028. As these devices are long lasting and efficient which is the major driver boosting the demand of the neuropathic pain market in the forecast period. Growing prevalence of chronic pain and neuropathic pain condition associated with many diseases will act as a driver for the growth of the neuropathic pain market.

Neuropathic pain is caused by a lesion or disease of the somatosensory system including peripheral fibres (Aβ, Aδ and C fibres) and central neurons and affects 7–10% of the general population. Multiple causes of neuropathic pain have been described and its incidence is likely to increase owing to the aging global population, increased incidence of diabetes mellitus and improved survival from cancer after chemotherapy.

Increasing R&D expenditure by various market players to create advanced products is expected to drive the growth of the neuropathic pain market. Limitation associated with the medical devices which limits the use of products is expected to act as restraint for the growth of the neuropathic pain market. High risk of neuropathic pain with ageing and rising older population in many countries will create an opportunity for the growth of the neuropathic pain market. Use of traditional therapies in emerging countries due to low health expenditure and disrupted supply chain is expected to act as a challenge for the growth of the neuropathic pain market.

The neuropathic pain market report provides details of market share, new developments, and product pipeline analysis, impact of domestic and localised market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, product approvals, strategic decisions, product launches, geographic expansions, and technological innovations in the market. To understand the analysis and the market scenario contact us for an Analyst Brief, our team will help you create a revenue impact solution to achieve your desired goal.

Asia-Pacific Neuropathic Pain Market Neuropathic Pain Market Scope and Market Size

The neuropathic pain market is segmented on the basis of the type, product type, procedure, technology, modality, mode of purchase, pain type, indication, end user and distribution channel. The growth among segments helps you analyse niche pockets of growth and strategies to approach the market and determine your core application areas and the difference in your target markets.

  • On the basis of type, the neuropathic pain market is segmented into spinal cord stimulation (SCS) devices, external peripheral nerve stimulation and transcutaneous electrical nerve stimulation (TENS) devices. In 2021, spinal cord stimulation (SCS) devices segment dominate the neuropathic pain market due to the vast usage of these devices for various neuropathic pain indications and the wide range of the products available in the market.
  • On the basis of product type, the neuropathic pain market is segmented into rechargeable and non-rechargeable. In 2021, the rechargeable segment is expected to show significant growth because rechargeable devices avoid the discharged battery's surgical replacement in traditional devices.
  • On the basis of procedure, the neuropathic pain market is segmented into invasive and non-invasive. In 2021, the invasive segment is expected to dominate the market because these devices available in the market are generally operating by invasive procedures that generally provide better efficiency for neuropathic pain.
  • On the basis of technology, the neuropathic pain market is segmented into transcutaneous electrical nerve stimulation, transcranial magnetic stimulation and respiratory electrical stimulation. In 2021, the transcutaneous electrical nerve stimulation segment is expected to show significant growth because transcutaneous electrical nerve stimulation is a non-invasive, inexpensive, self-administered technique to relieve pain due to the growing technological advancement, these devices are increasing their market size.
  • On the basis of modality, the neuropathic pain market is segmented into stationary and portable. In 2021, the stationary devices segment is expected to show significant growth rate due to rising incidences of chronic diseases such as cancer, cardiovascular, neurovascular disease and musculoskeletal diseases which generally include RF generators and other devices which are stationary in nature.
  • On the basis of mode of purchase, the neuropathic pain market is segmented into over-the-counter devices and prescription-based devices. In 2021, the prescription-based devices segment is expected to dominate the market due to the wide range of products available as = prescription-based devices increase the market share of the segment.
  • On the basis of pain type, the neuropathic pain market is segmented into peripheral neuropathy, entrapment neuropathy, phantom limb neuropathy, trigeminal neuralgia, post herpetic neuralgia, (PHN) post traumatic neuropathy, foot pain and coccydynia. In 2021, the peripheral neuropathy segment is expected to show the significant growth due to the increasing prevalence of peripheral neuropathy across the globe.
  • On the basis of indication, the neuropathic pain market is segmented into spinal stenosis, chemotherapy-induced peripheral neuropathy, diabetic neuropathy and others. In 2021, the diabetic neuropathy segment is likely to dominate the market due to the changing lifestyle pattern resulting in rising cases of diabetic patients at an early age.
  • On the basis of end user, the neuropathic pain market is segmented into hospitals, clinics, home healthcare, ambulatory surgical centers and others. In 2021, the hospitals segment is growing due to trained professionals as the hospitals department has a well-trained staffs with a professional team for proper and better treatment of the patients.
  • On the basis of distribution channel, the neuropathic pain market is segmented into direct tender, third party distributor and others. In 2021, direct tender segment accelerates the revenue growth and provides tax benefits owing to which the direct tender segment is flourishing for the last few years.

Neuropathic Pain Market Country Level Analysis

The neuropathic pain market is analysed and market size information is provided by the country, type, product type, procedure, technology, modality, mode of purchase, pain type, indication, end user and distribution channel as referenced above.

The countries covered in the Asia-Pacific neuropathic pain market report are the China, South Korea, Japan, India, Australia, Singapore, Malaysia, Indonesia, Thailand, Philippines and rest of Asia-Pacific.

China is leading country in the growth of the Asia-Pacific neuropathic pain market due to growing prevalence of chronic pain as well as technology advancement in healthcare sector.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, regulatory acts and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of sales channels are considered while providing forecast analysis of the country data.

Growing Strategic Activities by Major Market Players to Enhance the Awareness for Neuropathic Pain, is Boosting the Market Growth of Neuropathic Pain Market.

Neuropathic pain market also provides you with detailed market analysis for every country growth in neuropathic pain industry. Moreover, it provides detailed information regarding neuropathic pain sales, impact of regulatory scenarios, and trending parameters regarding neuropathic pain market. The data is available for historic period 2010 to 2019.

Competitive Landscape and Neuropathic Pain Market Share Analysis

Neuropathic pain market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, production sites and facilities, company strengths and weaknesses, product launch, product trials pipelines, product approvals, patents, product width and breadth, application dominance, technology lifeline curve. The above data points provided are only related to the company’s focus related to neuropathic pain market.

The major companies providing Neuropathic pain in the global Neuropathic pain market are NERVO CORP., AVNS, Integer Holdings Corporation, B. Braun Melsungen AG, Medtronic, Abbott, Boston Scientific Corporation, and Omron Healthcare Inc. among others.

Many contracts and agreements are also initiated by the companies’ worldwide which are also accelerating the neuropathic pain market.

  • In December 2021, Boston Scientific Corporation announced that they have launched WaveWriter Alpha Spinal Cord Stimulator Systems. This product is used for chronic pain and can be used in neuropathic pain. This launch will add up to the company's revenue and gain the market share in the forecasted period.

Collaboration, joint ventures and other strategies by the market players enhance the company footprints in the neuropathic pain market which also provides the benefit for the organisation in its growth pace.

Customization Available: Asia-Pacific Neuropathic Pain Market

Data Bridge Market Research is a leader in advanced formative research. We take pride in servicing our existing and new customers with data and analysis that match and suits their goal. The report can be customized to include price trend analysis of target brands understanding the market for additional countries (ask for the list of countries), clinical trial results data, literature review, refurbished market and product base analysis. Market analysis of target competitors can be analyzed from technology-based analysis to market portfolio strategies. We can add as many competitors that you require data about in the format and data style you are looking for. Our team of analysts can also provide you data in crude raw excel files pivot tables (Fact book) or can assist you in creating presentations from the data sets available in the report.


SKU-

TABLE 1 ASIA PACIFIC NEUROPATHIC PAIN MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 2 ASIA PACIFIC SPINAL CORD STIMULATION (SCS) DEVICES IN NEUROPATHIC PAIN MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 3 ASIA PACIFIC SPINAL CORD STIMULATION (SCS) DEVICES IN NEUROPATHIC PAIN MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 4 ASIA PACIFIC EXTERNAL PERIPHERAL NERVE STIMULATIONIN NEUROPATHIC PAIN MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 5 ASIA PACIFIC EXTERNAL PERIPHERAL NERVE STIMULATIONIN NEUROPATHIC PAIN MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 6 ASIA PACIFIC DEEP BRAIN STIMULATORS (DBS) IN NEUROPATHIC PAIN MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 7 ASIA PACIFIC TRANSCUTANEOUS ELECTRICAL NERVE STIMULATION (TENS) DEVICES IN NEUROPATHIC PAIN MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 8 ASIA PACIFIC TRANSCUTANEOUS ELECTRICAL NERVE STIMULATION (TENS) DEVICES IN NEUROPATHIC PAIN MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 9 ASIA PACIFIC NEUROPATHIC PAIN MARKET, BY PRODUCT TYPE, 2019-2028 (USD MILLION)

TABLE 10 ASIA PACIFIC RECHARGEABLE IN NEUROPATHIC PAIN MARKET, BY PRODUCT TYPE, 2019-2028 (USD MILLION)

TABLE 11 ASIA PACIFIC NON-RECHARGEABLE NEUROPATHIC PAIN MARKET, BY PRODUCT TYPE, 2019-2028 (USD MILLION)

TABLE 12 ASIA PACIFIC NEUROPATHIC PAIN DEVICE MARKET, BY PROCEDURE, 2019-2028 (USD MILLION)

TABLE 13 ASIA PACIFIC NON-INVASIVE INVASIVE IN NEUROPATHIC PAIN DEVICE MARKET, BY PROCEDURE, 2019-2028 (USD MILLION)

TABLE 14 ASIA PACIFIC INVASIVE IN NEUROENDOCRINE TUMORS MARKET, BY CLASSIFICATION 2019-2027 (USD MILLION)

TABLE 15 ASIA PACIFIC NEUROPATHIC PAIN MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)

TABLE 16 ASIA PACIFIC TRANSCUTANEOUS ELECTRICAL NERVE STIMULATION NEUROPATHIC PAIN MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)

TABLE 17 ASIA PACIFIC TRANSCRANIAL MAGNETIC STIMULATION NEUROPATHIC PAIN MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)

TABLE 18 ASIA PACIFIC RESPIRATORY ELECTRICAL STIMULATION NEUROPATHIC PAIN MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)

TABLE 19 ASIA PACIFIC NEUROPATHIC PAIN MARKET, BY MODALITY, 2019-2028 (USD MILLION)

TABLE 20 ASIA PACIFIC PORTABLE NEUROPATHIC PAIN MARKET, BY MODALITY, 2019-2028 (USD MILLION)

TABLE 21 ASIA PACIFIC PORTABLE IN NEUROPATHIC PAIN MARKET, BY MODALITY, 2019-2028 (USD MILLION)

TABLE 22 ASIA PACIFIC STATIONARY NEUROPATHIC PAIN MARKET, BY MODALITY, 2019-2028 (USD MILLION)

TABLE 23 ASIA PACIFIC STATIONARY NEUROPATHIC PAIN MARKET, BY MODALITY, 2019-2028 (USD MILLION)

TABLE 24 ASIA PACIFIC NEUROPATHIC PAIN MARKET, BY MODE OF PURCHASE, 2019-2028 (USD MILLION)

TABLE 25 ASIA PACIFIC PRESCRIPTION-BASED DEVICES NEUROPATHIC PAIN MARKET, BY MODE OF PURCHASE, 2019-2028 (USD MILLION)

TABLE 26 ASIA PACIFIC OVER-THE-COUNTER DEVICES NEUROPATHIC PAIN MARKET, BY MODE OF PURCHASE, 2019-2028 (USD MILLION)

TABLE 27 ASIA PACIFIC NEUROPATHIC PAIN MARKET, BY PAIN TYPE, 2019-2028 (USD MILLION)

TABLE 28 ASIA PACIFIC PERIPHERAL NEUROPATHY NEUROPATHIC PAIN MARKET, BY PAIN TYPE, 2019-2028 (USD MILLION)

TABLE 29 ASIA PACIFIC PHANTOM LIMB PAIN NEUROPATHIC PAIN MARKET, BY PAIN TYPE, 2019-2028 (USD MILLION)

TABLE 30 ASIA PACIFIC POST HERPETIC NEURALGIA (PHN) NEUROPATHIC PAIN MARKET, BY PAIN TYPE, 2019-2028 (USD MILLION)

TABLE 31 ASIA PACIFIC POST TRAUMATIC NEUROPATHYNEUROPATHIC PAIN MARKET, BY PAIN TYPE, 2019-2028 (USD MILLION)

TABLE 32 ASIA PACIFIC ENTRAPMENT NEUROPATHY NEUROPATHIC PAIN MARKET, BY PAIN TYPE, 2019-2028 (USD MILLION)

TABLE 33 ASIA PACIFIC FOOT PAIN NEUROPATHIC PAIN MARKET, BY PAIN TYPE, 2019-2028 (USD MILLION)

TABLE 34 ASIA PACIFIC TRIGEMINAL NEURALGIA NEUROPATHIC PAIN MARKET, BY PAIN TYPE, 2019-2028 (USD MILLION)

TABLE 35 ASIA PACIFIC COCCYDYNIA NEUROPATHIC PAIN MARKET, BY PAIN TYPE, 2019-2028 (USD MILLION)

TABLE 36 ASIA PACIFIC OTHERS NEUROPATHIC PAIN MARKET, BY PAIN TYPE, 2019-2028 (USD MILLION)

TABLE 37 ASIA PACIFIC NEUROPATHIC PAIN MARKET, BY INDICATION, 2019-2028 (USD MILLION)

TABLE 38 ASIA PACIFIC SPINAL STENOSIS NEUROPATHIC PAIN MARKET, BY INDICATION, 2019-2028 (USD MILLION)

TABLE 39 ASIA PACIFIC SPINAL STENOSIS IN NEUROPATHIC PAIN MARKET, BY INDICATION, 2019-2028 (USD MILLION)

TABLE 40 ASIA PACIFIC DIABETIC NEUROPATHY NEUROPATHIC PAIN MARKET, BY INDICATION, 2019-2028 (USD MILLION)

TABLE 41 ASIA PACIFIC DIABETIC NEUROPATHY IN NEUROPATHIC PAIN MARKET, BY INDICATION, 2019-2028 (USD MILLION)

TABLE 42 ASIA PACIFIC CHEMOTHERAPY-INDUCED PERIPHERAL NEUROPATHY NEUROPATHIC PAIN MARKET, BY INDICATION, 2019-2028 (USD MILLION)

TABLE 43 ASIA PACIFIC CHEMOTHERAPY-INDUCED PERIPHERAL NEUROPATHY IN NEUROPATHIC PAIN MARKET, BY INDICATION, 2019-2028 (USD MILLION)

TABLE 44 ASIA PACIFIC OTHERS NEUROPATHIC PAIN MARKET, BY INDICATION, 2019-2028 (USD MILLION)

TABLE 45 ASIA PACIFIC NEUROPATHIC PAIN MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 46 ASIA PACIFIC CLINICS NEUROPATHIC PAIN MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 47 ASIA PACIFIC HOSPITALS NEUROPATHIC PAIN MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 48 ASIA PACIFIC HOSPITALS IN NEUROPATHIC PAIN MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 49 ASIA PACIFIC HOME HEALTHCARE NEUROPATHIC PAIN MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 50 ASIA PACIFIC AMBULATORY SURGICAL CENTERS NEUROPATHIC PAIN MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 51 ASIA PACIFIC OTHERS NEUROPATHIC PAIN MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 52 ASIA PACIFIC NEUROPATHIC PAIN MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 53 ASIA PACIFIC DIRECT TENDERS NEUROPATHIC PAIN MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 54 ASIA PACIFIC THIRD PARTY DISTRIBUTION NEUROPATHIC PAIN MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 55 ASIA PACIFIC OTHERS NEUROPATHIC PAIN MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 56 ASIA PACIFIC NEUROPATHIC PAIN MARKET, BY REGION , 2021-2028 (USD MILLION)

TABLE 57 ASIA-PACIFIC NEUROPATHIC PAIN MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 58 ASIA-PACIFIC NEUROPATHIC PAIN MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 59 ASIA-PACIFIC SPINAL CORD STIMULATION (SCS) DEVICES IN NEUROPATHIC PAIN MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 60 ASIA-PACIFIC EXTERNAL PERIPHERAL NERVE STIMULATION IN NEUROPATHIC PAIN MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 61 ASIA-PACIFIC DEEP BRAIN STIMULATORS (DBS) IN NEUROPATHIC PAIN MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 62 ASIA-PACIFIC TRANSCUTANEOUS ELECTRICAL NERVE STIMULATION (TENS) DEVICES IN NEUROPATHIC PAIN MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 63 ASIA-PACIFIC NEUROPATHIC PAIN MARKET, BY PRODUCT TYPE, 2019-2028 (USD MILLION)

TABLE 64 ASIA-PACIFIC NEUROPATHIC PAIN MARKET, BY PROCEDURE, 2019-2028 (USD MILLION)

TABLE 65 ASIA-PACIFIC NEUROPATHIC PAIN MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)

TABLE 66 ASIA-PACIFIC NEUROPATHIC PAIN MARKET, BY MODALITY, 2019-2028 (USD MILLION)

TABLE 67 ASIA-PACIFIC STATIONARY IN NEUROPATHIC PAIN MARKET, BY MODALITY, 2019-2028 (USD MILLION)

TABLE 68 ASIA-PACIFIC PORTABLE IN NEUROPATHIC PAIN MARKET, BY MODALITY, 2019-2028 (USD MILLION)

TABLE 69 ASIA-PACIFIC NEUROPATHIC PAIN MARKET, BY MODE OF PURCHASE, 2019-2028 (USD MILLION)

TABLE 70 ASIA-PACIFIC NEUROPATHIC PAIN MARKET, BY PAIN TYPE, 2019-2028 (USD MILLION)

TABLE 71 ASIA-PACIFIC NEUROPATHIC PAIN MARKET, BY INDICATION, 2019-2028 (USD MILLION)

TABLE 72 ASIA-PACIFIC SPINAL STENOSIS IN NEUROPATHIC PAIN MARKET, BY INDICATION, 2019-2028 (USD MILLION)

TABLE 73 ASIA-PACIFIC CHEMOTHERAPY-INDUCED PERIPHERAL NEUROPATHY IN NEUROPATHIC PAIN MARKET, BY INDICATION, 2019-2028 (USD MILLION)

TABLE 74 ASIA-PACIFIC DIABETIC NEUROPATHY IN NEUROPATHIC PAIN MARKET, BY INDICATION, 2019-2028 (USD MILLION)

TABLE 75 ASIA-PACIFIC NEUROPATHIC PAIN MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 76 ASIA-PACIFIC HOSPITALS IN NEUROPATHIC PAIN MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 77 ASIA-PACIFIC NEUROPATHIC PAIN MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 78 CHINA NEUROPATHIC PAIN MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 79 CHINA SPINAL CORD STIMULATION (SCS) DEVICES IN NEUROPATHIC PAIN MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 80 CHINA EXTERNAL PERIPHERAL NERVE STIMULATION IN NEUROPATHIC PAIN MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 81 CHINA DEEP BRAIN STIMULATORS (DBS) IN NEUROPATHIC PAIN MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 82 CHINA TRANSCUTANEOUS ELECTRICAL NERVE STIMULATION (TENS) DEVICES IN NEUROPATHIC PAIN MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 83 CHINA NEUROPATHIC PAIN MARKET, BY PRODUCT TYPE, 2019-2028 (USD MILLION)

TABLE 84 CHINA NEUROPATHIC PAIN MARKET, BY PROCEDURE, 2019-2028 (USD MILLION)

TABLE 85 CHINA NEUROPATHIC PAIN MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)

TABLE 86 CHINA NEUROPATHIC PAIN MARKET, BY MODALITY, 2019-2028 (USD MILLION)

TABLE 87 CHINA STATIONARY IN NEUROPATHIC PAIN MARKET, BY MODALITY, 2019-2028 (USD MILLION)

TABLE 88 CHINA PORTABLE IN NEUROPATHIC PAIN MARKET, BY MODALITY, 2019-2028 (USD MILLION)

TABLE 89 CHINA NEUROPATHIC PAIN MARKET, BY MODE OF PURCHASE, 2019-2028 (USD MILLION)

TABLE 90 CHINA NEUROPATHIC PAIN MARKET, BY PAIN TYPE, 2019-2028 (USD MILLION)

TABLE 91 CHINA NEUROPATHIC PAIN MARKET, BY INDICATION, 2019-2028 (USD MILLION)

TABLE 92 CHINA SPINAL STENOSIS IN NEUROPATHIC PAIN MARKET, BY INDICATION, 2019-2028 (USD MILLION)

TABLE 93 CHINA CHEMOTHERAPY-INDUCED PERIPHERAL NEUROPATHY IN NEUROPATHIC PAIN MARKET, BY INDICATION, 2019-2028 (USD MILLION)

TABLE 94 CHINA DIABETIC NEUROPATHY IN NEUROPATHIC PAIN MARKET, BY INDICATION, 2019-2028 (USD MILLION)

TABLE 95 CHINA NEUROPATHIC PAIN MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 96 CHINA HOSPITALS IN NEUROPATHIC PAIN MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 97 CHINA NEUROPATHIC PAIN MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 98 JAPAN NEUROPATHIC PAIN MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 99 JAPAN SPINAL CORD STIMULATION (SCS) DEVICES IN NEUROPATHIC PAIN MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 100 JAPAN EXTERNAL PERIPHERAL NERVE STIMULATION IN NEUROPATHIC PAIN MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 101 JAPAN DEEP BRAIN STIMULATORS (DBS) IN NEUROPATHIC PAIN MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 102 JAPAN TRANSCUTANEOUS ELECTRICAL NERVE STIMULATION (TENS) DEVICES IN NEUROPATHIC PAIN MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 103 JAPAN NEUROPATHIC PAIN MARKET, BY PRODUCT TYPE, 2019-2028 (USD MILLION)

TABLE 104 JAPAN NEUROPATHIC PAIN MARKET, BY PROCEDURE, 2019-2028 (USD MILLION)

TABLE 105 JAPAN NEUROPATHIC PAIN MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)

TABLE 106 JAPAN NEUROPATHIC PAIN MARKET, BY MODALITY, 2019-2028 (USD MILLION)

TABLE 107 JAPAN STATIONARY IN NEUROPATHIC PAIN MARKET, BY MODALITY, 2019-2028 (USD MILLION)

TABLE 108 JAPAN PORTABLE IN NEUROPATHIC PAIN MARKET, BY MODALITY, 2019-2028 (USD MILLION)

TABLE 109 JAPAN NEUROPATHIC PAIN MARKET, BY MODE OF PURCHASE, 2019-2028 (USD MILLION)

TABLE 110 JAPAN NEUROPATHIC PAIN MARKET, BY PAIN TYPE, 2019-2028 (USD MILLION)

TABLE 111 JAPAN NEUROPATHIC PAIN MARKET, BY INDICATION, 2019-2028 (USD MILLION)

TABLE 112 JAPAN SPINAL STENOSIS IN NEUROPATHIC PAIN MARKET, BY INDICATION, 2019-2028 (USD MILLION)

TABLE 113 JAPAN CHEMOTHERAPY-INDUCED PERIPHERAL NEUROPATHY IN NEUROPATHIC PAIN MARKET, BY INDICATION, 2019-2028 (USD MILLION)

TABLE 114 JAPAN DIABETIC NEUROPATHY IN NEUROPATHIC PAIN MARKET, BY INDICATION, 2019-2028 (USD MILLION)

TABLE 115 JAPAN NEUROPATHIC PAIN MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 116 JAPAN HOSPITALS IN NEUROPATHIC PAIN MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 117 JAPAN NEUROPATHIC PAIN MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 118 AUSTRALIA NEUROPATHIC PAIN MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 119 AUSTRALIA SPINAL CORD STIMULATION (SCS) DEVICES IN NEUROPATHIC PAIN MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 120 AUSTRALIA EXTERNAL PERIPHERAL NERVE STIMULATION IN NEUROPATHIC PAIN MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 121 AUSTRALIA DEEP BRAIN STIMULATORS (DBS) IN NEUROPATHIC PAIN MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 122 AUSTRALIA TRANSCUTANEOUS ELECTRICAL NERVE STIMULATION (TENS) DEVICES IN NEUROPATHIC PAIN MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 123 AUSTRALIA NEUROPATHIC PAIN MARKET, BY PRODUCT TYPE, 2019-2028 (USD MILLION)

TABLE 124 AUSTRALIA NEUROPATHIC PAIN MARKET, BY PROCEDURE, 2019-2028 (USD MILLION)

TABLE 125 AUSTRALIA NEUROPATHIC PAIN MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)

TABLE 126 AUSTRALIA NEUROPATHIC PAIN MARKET, BY MODALITY, 2019-2028 (USD MILLION)

TABLE 127 AUSTRALIA STATIONARY IN NEUROPATHIC PAIN MARKET, BY MODALITY, 2019-2028 (USD MILLION)

TABLE 128 AUSTRALIA PORTABLE IN NEUROPATHIC PAIN MARKET, BY MODALITY, 2019-2028 (USD MILLION)

TABLE 129 AUSTRALIA NEUROPATHIC PAIN MARKET, BY MODE OF PURCHASE, 2019-2028 (USD MILLION)

TABLE 130 AUSTRALIA NEUROPATHIC PAIN MARKET, BY PAIN TYPE, 2019-2028 (USD MILLION)

TABLE 131 AUSTRALIA NEUROPATHIC PAIN MARKET, BY INDICATION, 2019-2028 (USD MILLION)

TABLE 132 AUSTRALIA SPINAL STENOSIS IN NEUROPATHIC PAIN MARKET, BY INDICATION, 2019-2028 (USD MILLION)

TABLE 133 AUSTRALIA CHEMOTHERAPY-INDUCED PERIPHERAL NEUROPATHY IN NEUROPATHIC PAIN MARKET, BY INDICATION, 2019-2028 (USD MILLION)

TABLE 134 AUSTRALIA DIABETIC NEUROPATHY IN NEUROPATHIC PAIN MARKET, BY INDICATION, 2019-2028 (USD MILLION)

TABLE 135 AUSTRALIA NEUROPATHIC PAIN MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 136 AUSTRALIA HOSPITALS IN NEUROPATHIC PAIN MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 137 AUSTRALIA NEUROPATHIC PAIN MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 138 INDIA NEUROPATHIC PAIN MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 139 INDIA SPINAL CORD STIMULATION (SCS) DEVICES IN NEUROPATHIC PAIN MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 140 INDIA EXTERNAL PERIPHERAL NERVE STIMULATION IN NEUROPATHIC PAIN MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 141 INDIA DEEP BRAIN STIMULATORS (DBS) IN NEUROPATHIC PAIN MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 142 INDIA TRANSCUTANEOUS ELECTRICAL NERVE STIMULATION (TENS) DEVICES IN NEUROPATHIC PAIN MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 143 INDIA NEUROPATHIC PAIN MARKET, BY PRODUCT TYPE, 2019-2028 (USD MILLION)

TABLE 144 INDIA NEUROPATHIC PAIN MARKET, BY PROCEDURE, 2019-2028 (USD MILLION)

TABLE 145 INDIA NEUROPATHIC PAIN MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)

TABLE 146 INDIA NEUROPATHIC PAIN MARKET, BY MODALITY, 2019-2028 (USD MILLION)

TABLE 147 INDIA STATIONARY IN NEUROPATHIC PAIN MARKET, BY MODALITY, 2019-2028 (USD MILLION)

TABLE 148 INDIA PORTABLE IN NEUROPATHIC PAIN MARKET, BY MODALITY, 2019-2028 (USD MILLION)

TABLE 149 INDIA NEUROPATHIC PAIN MARKET, BY MODE OF PURCHASE, 2019-2028 (USD MILLION)

TABLE 150 INDIA NEUROPATHIC PAIN MARKET, BY PAIN TYPE, 2019-2028 (USD MILLION)

TABLE 151 INDIA NEUROPATHIC PAIN MARKET, BY INDICATION, 2019-2028 (USD MILLION)

TABLE 152 INDIA SPINAL STENOSIS IN NEUROPATHIC PAIN MARKET, BY INDICATION, 2019-2028 (USD MILLION)

TABLE 153 INDIA CHEMOTHERAPY-INDUCED PERIPHERAL NEUROPATHY IN NEUROPATHIC PAIN MARKET, BY INDICATION, 2019-2028 (USD MILLION)

TABLE 154 INDIA DIABETIC NEUROPATHY IN NEUROPATHIC PAIN MARKET, BY INDICATION, 2019-2028 (USD MILLION)

TABLE 155 INDIA NEUROPATHIC PAIN MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 156 INDIA HOSPITALS IN NEUROPATHIC PAIN MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 157 INDIA NEUROPATHIC PAIN MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 158 SOUTH KOREA NEUROPATHIC PAIN MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 159 SOUTH KOREA SPINAL CORD STIMULATION (SCS) DEVICES IN NEUROPATHIC PAIN MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 160 SOUTH KOREA EXTERNAL PERIPHERAL NERVE STIMULATION IN NEUROPATHIC PAIN MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 161 SOUTH KOREA DEEP BRAIN STIMULATORS (DBS) IN NEUROPATHIC PAIN MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 162 SOUTH KOREA TRANSCUTANEOUS ELECTRICAL NERVE STIMULATION (TENS) DEVICES IN NEUROPATHIC PAIN MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 163 SOUTH KOREA NEUROPATHIC PAIN MARKET, BY PRODUCT TYPE, 2019-2028 (USD MILLION)

TABLE 164 SOUTH KOREA NEUROPATHIC PAIN MARKET, BY PROCEDURE, 2019-2028 (USD MILLION)

TABLE 165 SOUTH KOREA NEUROPATHIC PAIN MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)

TABLE 166 SOUTH KOREA NEUROPATHIC PAIN MARKET, BY MODALITY, 2019-2028 (USD MILLION)

TABLE 167 SOUTH KOREA STATIONARY IN NEUROPATHIC PAIN MARKET, BY MODALITY, 2019-2028 (USD MILLION)

TABLE 168 SOUTH KOREA PORTABLE IN NEUROPATHIC PAIN MARKET, BY MODALITY, 2019-2028 (USD MILLION)

TABLE 169 SOUTH KOREA NEUROPATHIC PAIN MARKET, BY MODE OF PURCHASE, 2019-2028 (USD MILLION)

TABLE 170 SOUTH KOREA NEUROPATHIC PAIN MARKET, BY PAIN TYPE, 2019-2028 (USD MILLION)

TABLE 171 SOUTH KOREA NEUROPATHIC PAIN MARKET, BY INDICATION, 2019-2028 (USD MILLION)

TABLE 172 SOUTH KOREA SPINAL STENOSIS IN NEUROPATHIC PAIN MARKET, BY INDICATION, 2019-2028 (USD MILLION)

TABLE 173 SOUTH KOREA CHEMOTHERAPY-INDUCED PERIPHERAL NEUROPATHY IN NEUROPATHIC PAIN MARKET, BY INDICATION, 2019-2028 (USD MILLION)

TABLE 174 SOUTH KOREA DIABETIC NEUROPATHY IN NEUROPATHIC PAIN MARKET, BY INDICATION, 2019-2028 (USD MILLION)

TABLE 175 SOUTH KOREA NEUROPATHIC PAIN MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 176 SOUTH KOREA HOSPITALS IN NEUROPATHIC PAIN MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 177 SOUTH KOREA NEUROPATHIC PAIN MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 178 SINGAPORE NEUROPATHIC PAIN MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 179 SINGAPORE SPINAL CORD STIMULATION (SCS) DEVICES IN NEUROPATHIC PAIN MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 180 SINGAPORE EXTERNAL PERIPHERAL NERVE STIMULATION IN NEUROPATHIC PAIN MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 181 SINGAPORE DEEP BRAIN STIMULATORS (DBS) IN NEUROPATHIC PAIN MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 182 SINGAPORE TRANSCUTANEOUS ELECTRICAL NERVE STIMULATION (TENS) DEVICES IN NEUROPATHIC PAIN MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 183 SINGAPORE NEUROPATHIC PAIN MARKET, BY PRODUCT TYPE, 2019-2028 (USD MILLION)

TABLE 184 SINGAPORE NEUROPATHIC PAIN MARKET, BY PROCEDURE, 2019-2028 (USD MILLION)

TABLE 185 SINGAPORE NEUROPATHIC PAIN MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)

TABLE 186 SINGAPORE NEUROPATHIC PAIN MARKET, BY MODALITY, 2019-2028 (USD MILLION)

TABLE 187 SINGAPORE STATIONARY IN NEUROPATHIC PAIN MARKET, BY MODALITY, 2019-2028 (USD MILLION)

TABLE 188 SINGAPORE PORTABLE IN NEUROPATHIC PAIN MARKET, BY MODALITY, 2019-2028 (USD MILLION)

TABLE 189 SINGAPORE NEUROPATHIC PAIN MARKET, BY MODE OF PURCHASE, 2019-2028 (USD MILLION)

TABLE 190 SINGAPORE NEUROPATHIC PAIN MARKET, BY PAIN TYPE, 2019-2028 (USD MILLION)

TABLE 191 SINGAPORE NEUROPATHIC PAIN MARKET, BY INDICATION, 2019-2028 (USD MILLION)

TABLE 192 SINGAPORE SPINAL STENOSIS IN NEUROPATHIC PAIN MARKET, BY INDICATION, 2019-2028 (USD MILLION)

TABLE 193 SINGAPORE CHEMOTHERAPY-INDUCED PERIPHERAL NEUROPATHY IN NEUROPATHIC PAIN MARKET, BY INDICATION, 2019-2028 (USD MILLION)

TABLE 194 SINGAPORE DIABETIC NEUROPATHY IN NEUROPATHIC PAIN MARKET, BY INDICATION, 2019-2028 (USD MILLION)

TABLE 195 SINGAPORE NEUROPATHIC PAIN MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 196 SINGAPORE HOSPITALS IN NEUROPATHIC PAIN MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 197 SINGAPORE NEUROPATHIC PAIN MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 198 MALAYSIA NEUROPATHIC PAIN MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 199 MALAYSIA SPINAL CORD STIMULATION (SCS) DEVICES IN NEUROPATHIC PAIN MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 200 MALAYSIA EXTERNAL PERIPHERAL NERVE STIMULATION IN NEUROPATHIC PAIN MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 201 MALAYSIA DEEP BRAIN STIMULATORS (DBS) IN NEUROPATHIC PAIN MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 202 MALAYSIA TRANSCUTANEOUS ELECTRICAL NERVE STIMULATION (TENS) DEVICES IN NEUROPATHIC PAIN MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 203 MALAYSIA NEUROPATHIC PAIN MARKET, BY PRODUCT TYPE, 2019-2028 (USD MILLION)

TABLE 204 MALAYSIA NEUROPATHIC PAIN MARKET, BY PROCEDURE, 2019-2028 (USD MILLION)

TABLE 205 MALAYSIA NEUROPATHIC PAIN MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)

TABLE 206 MALAYSIA NEUROPATHIC PAIN MARKET, BY MODALITY, 2019-2028 (USD MILLION)

TABLE 207 MALAYSIA STATIONARY IN NEUROPATHIC PAIN MARKET, BY MODALITY, 2019-2028 (USD MILLION)

TABLE 208 MALAYSIA PORTABLE IN NEUROPATHIC PAIN MARKET, BY MODALITY, 2019-2028 (USD MILLION)

TABLE 209 MALAYSIA NEUROPATHIC PAIN MARKET, BY MODE OF PURCHASE, 2019-2028 (USD MILLION)

TABLE 210 MALAYSIA NEUROPATHIC PAIN MARKET, BY PAIN TYPE, 2019-2028 (USD MILLION)

TABLE 211 MALAYSIA NEUROPATHIC PAIN MARKET, BY INDICATION, 2019-2028 (USD MILLION)

TABLE 212 MALAYSIA SPINAL STENOSIS IN NEUROPATHIC PAIN MARKET, BY INDICATION, 2019-2028 (USD MILLION)

TABLE 213 MALAYSIA CHEMOTHERAPY-INDUCED PERIPHERAL NEUROPATHY IN NEUROPATHIC PAIN MARKET, BY INDICATION, 2019-2028 (USD MILLION)

TABLE 214 MALAYSIA DIABETIC NEUROPATHY IN NEUROPATHIC PAIN MARKET, BY INDICATION, 2019-2028 (USD MILLION)

TABLE 215 MALAYSIA NEUROPATHIC PAIN MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 216 MALAYSIA HOSPITALS IN NEUROPATHIC PAIN MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 217 MALAYSIA NEUROPATHIC PAIN MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 218 THAILAND NEUROPATHIC PAIN MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 219 THAILAND SPINAL CORD STIMULATION (SCS) DEVICES IN NEUROPATHIC PAIN MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 220 THAILAND EXTERNAL PERIPHERAL NERVE STIMULATION IN NEUROPATHIC PAIN MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 221 THAILAND DEEP BRAIN STIMULATORS (DBS) IN NEUROPATHIC PAIN MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 222 THAILAND TRANSCUTANEOUS ELECTRICAL NERVE STIMULATION (TENS) DEVICES IN NEUROPATHIC PAIN MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 223 THAILAND NEUROPATHIC PAIN MARKET, BY PRODUCT TYPE, 2019-2028 (USD MILLION)

TABLE 224 THAILAND NEUROPATHIC PAIN MARKET, BY PROCEDURE, 2019-2028 (USD MILLION)

TABLE 225 THAILAND NEUROPATHIC PAIN MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)

TABLE 226 THAILAND NEUROPATHIC PAIN MARKET, BY MODALITY, 2019-2028 (USD MILLION)

TABLE 227 THAILAND STATIONARY IN NEUROPATHIC PAIN MARKET, BY MODALITY, 2019-2028 (USD MILLION)

TABLE 228 THAILAND PORTABLE IN NEUROPATHIC PAIN MARKET, BY MODALITY, 2019-2028 (USD MILLION)

TABLE 229 THAILAND NEUROPATHIC PAIN MARKET, BY MODE OF PURCHASE, 2019-2028 (USD MILLION)

TABLE 230 THAILAND NEUROPATHIC PAIN MARKET, BY PAIN TYPE, 2019-2028 (USD MILLION)

TABLE 231 THAILAND NEUROPATHIC PAIN MARKET, BY INDICATION, 2019-2028 (USD MILLION)

TABLE 232 THAILAND SPINAL STENOSIS IN NEUROPATHIC PAIN MARKET, BY INDICATION, 2019-2028 (USD MILLION)

TABLE 233 THAILAND CHEMOTHERAPY-INDUCED PERIPHERAL NEUROPATHY IN NEUROPATHIC PAIN MARKET, BY INDICATION, 2019-2028 (USD MILLION)

TABLE 234 THAILAND DIABETIC NEUROPATHY IN NEUROPATHIC PAIN MARKET, BY INDICATION, 2019-2028 (USD MILLION)

TABLE 235 THAILAND NEUROPATHIC PAIN MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 236 THAILAND HOSPITALS IN NEUROPATHIC PAIN MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 237 THAILAND NEUROPATHIC PAIN MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 238 INDONESIA NEUROPATHIC PAIN MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 239 INDONESIA SPINAL CORD STIMULATION (SCS) DEVICES IN NEUROPATHIC PAIN MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 240 INDONESIA EXTERNAL PERIPHERAL NERVE STIMULATION IN NEUROPATHIC PAIN MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 241 INDONESIA DEEP BRAIN STIMULATORS (DBS) IN NEUROPATHIC PAIN MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 242 INDONESIA TRANSCUTANEOUS ELECTRICAL NERVE STIMULATION (TENS) DEVICES IN NEUROPATHIC PAIN MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 243 INDONESIA NEUROPATHIC PAIN MARKET, BY PRODUCT TYPE, 2019-2028 (USD MILLION)

TABLE 244 INDONESIA NEUROPATHIC PAIN MARKET, BY PROCEDURE, 2019-2028 (USD MILLION)

TABLE 245 INDONESIA NEUROPATHIC PAIN MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)

TABLE 246 INDONESIA NEUROPATHIC PAIN MARKET, BY MODALITY, 2019-2028 (USD MILLION)

TABLE 247 INDONESIA STATIONARY IN NEUROPATHIC PAIN MARKET, BY MODALITY, 2019-2028 (USD MILLION)

TABLE 248 INDONESIA PORTABLE IN NEUROPATHIC PAIN MARKET, BY MODALITY, 2019-2028 (USD MILLION)

TABLE 249 INDONESIA NEUROPATHIC PAIN MARKET, BY MODE OF PURCHASE, 2019-2028 (USD MILLION)

TABLE 250 INDONESIA NEUROPATHIC PAIN MARKET, BY PAIN TYPE, 2019-2028 (USD MILLION)

TABLE 251 INDONESIA NEUROPATHIC PAIN MARKET, BY INDICATION, 2019-2028 (USD MILLION)

TABLE 252 INDONESIA SPINAL STENOSIS IN NEUROPATHIC PAIN MARKET, BY INDICATION, 2019-2028 (USD MILLION)

TABLE 253 INDONESIA CHEMOTHERAPY-INDUCED PERIPHERAL NEUROPATHY IN NEUROPATHIC PAIN MARKET, BY INDICATION, 2019-2028 (USD MILLION)

TABLE 254 INDONESIA DIABETIC NEUROPATHY IN NEUROPATHIC PAIN MARKET, BY INDICATION, 2019-2028 (USD MILLION)

TABLE 255 INDONESIA NEUROPATHIC PAIN MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 256 INDONESIA HOSPITALS IN NEUROPATHIC PAIN MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 257 INDONESIA NEUROPATHIC PAIN MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 258 PHILIPPINES NEUROPATHIC PAIN MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 259 PHILIPPINES SPINAL CORD STIMULATION (SCS) DEVICES IN NEUROPATHIC PAIN MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 260 PHILIPPINES EXTERNAL PERIPHERAL NERVE STIMULATION IN NEUROPATHIC PAIN MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 261 PHILIPPINES DEEP BRAIN STIMULATORS (DBS) IN NEUROPATHIC PAIN MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 262 PHILIPPINES TRANSCUTANEOUS ELECTRICAL NERVE STIMULATION (TENS) DEVICES IN NEUROPATHIC PAIN MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 263 PHILIPPINES NEUROPATHIC PAIN MARKET, BY PRODUCT TYPE, 2019-2028 (USD MILLION)

TABLE 264 PHILIPPINES NEUROPATHIC PAIN MARKET, BY PROCEDURE, 2019-2028 (USD MILLION)

TABLE 265 PHILIPPINES NEUROPATHIC PAIN MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)

TABLE 266 PHILIPPINES NEUROPATHIC PAIN MARKET, BY MODALITY, 2019-2028 (USD MILLION)

TABLE 267 PHILIPPINES STATIONARY IN NEUROPATHIC PAIN MARKET, BY MODALITY, 2019-2028 (USD MILLION)

TABLE 268 PHILIPPINES PORTABLE IN NEUROPATHIC PAIN MARKET, BY MODALITY, 2019-2028 (USD MILLION)

TABLE 269 PHILIPPINES NEUROPATHIC PAIN MARKET, BY MODE OF PURCHASE, 2019-2028 (USD MILLION)

TABLE 270 PHILIPPINES NEUROPATHIC PAIN MARKET, BY PAIN TYPE, 2019-2028 (USD MILLION)

TABLE 271 PHILIPPINES NEUROPATHIC PAIN MARKET, BY INDICATION, 2019-2028 (USD MILLION)

TABLE 272 PHILIPPINES SPINAL STENOSIS IN NEUROPATHIC PAIN MARKET, BY INDICATION, 2019-2028 (USD MILLION)

TABLE 273 PHILIPPINES CHEMOTHERAPY-INDUCED PERIPHERAL NEUROPATHY IN NEUROPATHIC PAIN MARKET, BY INDICATION, 2019-2028 (USD MILLION)

TABLE 274 PHILIPPINES DIABETIC NEUROPATHY IN NEUROPATHIC PAIN MARKET, BY INDICATION, 2019-2028 (USD MILLION)

TABLE 275 PHILIPPINES NEUROPATHIC PAIN MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 276 PHILIPPINES HOSPITALS IN NEUROPATHIC PAIN MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 277 PHILIPPINES NEUROPATHIC PAIN MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 278 REST OF ASIA-PACIFIC NEUROPATHIC PAIN MARKET, BY TYPE, 2019-2028 (USD MILLION)

CHOOSE LICENCE TYPE
  • 4200.00
  • 3500.00
  • 2000.00
  • 5500.00
  • 7500.00
Why Choose Us
Unlocking New Opportunities on this Report Post Covid-19

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions